



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/50, 33/53, 33/543 // 33/576		A1	(11) International Publication Number: WO 96/41164 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/07745 (22) International Filing Date: 24 May 1996 (24.05.96)		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/482,710 7 June 1995 (07.06.95) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 037/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).			
(72) Inventor: FIGARD, Steve, D.; 15206 W. Route 173, Zion, IL 60099 (US).			
(74) Agents: WEINSTEIN, David, L. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).			
(54) Title: BUFFER COMPOSITION FOR REAGENTS FOR IMMUNOASSAY			
(57) Abstract An aqueous composition suitable for use when performing immunological procedures. The composition includes at least one biological buffer, dithiothreitol (alternatively referred to herein as "DTT"), and ethylene glycol. The composition can also include at least one biological detergent, at least one source of positive and negative counterions, e.g., salt, and at least one viscosity modifier, e.g., sugar. The buffer also can include at least one preservative, such as sodium azide. The pH of the composition preferably ranges from about 6.4 to 7.2. A kit containing the composition is also disclosed.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

BUFFER COMPOSITION FOR REAGENTS FOR IMMUNOASSAY

5

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to buffering compositions, and more particularly, to buffering compositions useful for immunological and immunochemical assay components, such as antibodies and antigens.

2. Discussion of the art

Many types of immunoassays can be run on an apparatus of the type described in U.S. Patent No. 5,358, 691, incorporated herein by reference. In general, immunoassays can be classified into two major categories --- homogeneous and heterogeneous. Homogeneous and heterogeneous immunoassays depend upon the ability of a first binding member of a binding member pair, e.g., an antigen, to specifically bind to a second binding member of a binding member pair, e.g., an antibody. A conjugate, comprising one of such binding members labeled with a detectable moiety, is employed to determine the extent of such binding. For example, such binding member pairs can be an antigen and an antibody to such antigen. The conjugate, which can comprise the antigen, either participates in a binding reaction with the antibody or does not participate in such a reaction. The amount of detectable moiety detected and measured after the reaction can be correlated to the amount of antibody present in the test sample.

Heterogeneous assays can be performed in a competitive immunoassay format or in a sandwich immunoassay format. In the competitive immunoassay format, an antigen can be immobilized to a solid phase material whereby the amount of detectable moiety that is bound to a solid phase material can be detected, measured, and correlated to the amount of antibody present in the test sample. Examples of solid phase materials include beads, particles, microparticles, and the like. In the sandwich immunoassay format, a test sample containing, for example, an antibody is contacted with a protein such as an antigen. The antigen is immobilized on a solid phase material. Examples of

solid phase materials include beads, particles, microparticles, and the like. The solid phase material is typically treated with a second antigen or antibody that has been labeled with a detectable moiety. The second antigen or antibody then becomes bound to the corresponding antigen or antibody on the solid 5 phase material and, after one or more washing steps to remove any unbound material, an indicator material, such as a chromogenic substance, is introduced to react with the detectable moiety to produce a detectable signal, e.g., a color change. The color change is then detected, measured, and correlated to the amount of antibody present in the test sample. It should also be noted that 10 various diluents and buffers are also required to optimize the operation of the microparticles, antigens, conjugates, and other components of the assay that participate in chemical reactions.

A heterogeneous immunoassay that can be performed with the apparatus of U.S. Patent No. 5,358,691 in either a competitive or sandwich 15 immunoassay format is a microparticle capture enzyme immunoassay, such as that described in *Clinical Chemistry*, Volume 34, No. 9, pages 1726-1732 (1988), employing microparticles as the solid phase material. This article is incorporated herein by reference.

A step-by-step description of a microparticle capture enzyme 20 immunoassay procedure is set forth at col. 35, line 60 through col. 44, line 22 of U.S. Patent No. 5,358,691.

Various components of of kits used in immunoassays run on the apparatus described in U.S. Patent No. 5,358,691 must fulfill certain functional 25 requirements. The microparticles must provide a solid phase for antibody capture, serving as a support for the antigens used for said capture. These particles must themselves be captured, e.g., by a matrix cell filter, to permit detection of bound antibody by the conjugate/substrate combination. The microparticle diluent must provide a medium that maintains the antigens' ability 30 to be recognized by complementary antibodies in patient specimens (stability) while not inhibiting that recognition (signal generation). The conjugate must provide a means to specifically recognize antibodies bound to antigens on the microparticle and a means to generate a signal to indicate the presence of conjugate on the microparticle. The conjugate diluent must provide a medium 35 that preserves and optimizes the ability of one binding pair member on the conjugate to recognize its complementary binding pair member, while simultaneously preserving and optimizing the ability of the enzyme portion, e.g.,

alkaline phosphatase portion, to hydrolyze the substrate into a detectable entity. In addition, the conjugate diluent must contain components that will minimize, if not eliminate, nonspecific binding of the conjugate to the matrix or microparticle, thus preventing the generation of a false signal. The sample dilution buffer must 5 provide a medium that optimizes the ability of antibodies in a specimen to bind to antigen on the microparticles while preventing nonspecific interactions that might lead to the generation of a false signal

Because certain antigens used in immunoassays are unstable after prolonged exposure to heat, it would be desirable to increase the stability of 10 antigens to heat stress. Because antigens are characterized by certain epitopes, it would be desirable to increase the stability of the antigens by increasing the stability of the characteristic epitopes.

SUMMARY OF THE INVENTION

15

The present invention provides an aqueous composition suitable for use as a buffer, which composition comprises at least one biological buffer, dithiothreitol (alternatively referred to herein as "DTT"), and ethylene glycol. The medium of the composition is water. The composition can also include at 20 least one biological detergent, at least one source of positive and negative counterions, e.g., salt, and at least one viscosity modifier, e.g., sugar. The buffer also can include at least one preservative, e.g., sodium azide. The pH of the composition of the present invention can range from about 6.4 to about 7.2, preferably from about 6.4 to about 6.8, more preferably from about 6.5 to about 25 6.7. Most preferably, the pH of the composition is about 6.6.

The composition is particularly useful for stabilizing the immunoreactivity of antigens, e.g., hepatitis C virus (HCV) antigens of the NS3 region of the viral genome, under heat stress conditions, in particular, temperatures ranging from 31 to 37 °C. The composition of this invention has been found to be useful as a 30 diluent for microparticles for diagnostic assays in which antigens are passively coated onto polymeric microparticles. It has been found that the use of ethylene glycol significantly enhances the long-term ability of antigens to detect complementary antibodies that bind to the antigens disposed on the surface of a microparticle.

The composition of this invention provides immunoreactive stability to antigens and antibodies at elevated temperatures, e.g., 37 °C, for relatively long periods of time, e.g., 20 days.

5 In another aspect of the invention, a kit containing the composition as a component is also provided.

BRIEF DESCRIPTION OF THE DRAWING

10 FIG. 1 is a graph illustrating the advantageous effect of ethylene glycol upon the stability of 33c antigen, as evidenced by the ability to detect binding of anti-HCV antibodies to microparticles having 33c antigen coated thereon. The 33c antigen is a segment of the recombinant HCV protein HC43.

DETAILED DESCRIPTION OF THE INVENTION

15 This invention involves an aqueous composition that is particularly useful for improving stability of antigens and antibodies under heat stress conditions. The composition comprises the following ingredients: at least one a biological buffer, dithiothreitol [$\text{HSCH}_2(\text{CHOH})_2\text{CH}_2\text{SH}$], and ethylene glycol [$\text{HOCH}_2\text{CH}_2\text{OH}$]. The medium of the composition is water.

20 In the preferred embodiments of the invention, the composition further includes at least one biological detergent, at least one source of positive and negative counterions, e.g., salt, at least one viscosity modifier, e.g., sugar. A preservative, e.g., sodium azide, can also be added to the composition to 25 reduce microbial growth. The composition has a pH ranging from about 6.4 to about 7.2, more preferably from about 6.5 to about 6.7. If necessary, the pH of the composition can be adjusted with acid or base.

30 The function of the biological buffer is to maintain the pH of the medium at a constant level. It has been found that optimum results are obtained when the pKa of the buffer is within 1.0 pH unit of pH 6.6. In other words, the pKa of the buffer preferably ranges from 5.6 to 7.6.

Biological buffers that are suitable for the composition of the invention include, but are not limited to, the following acids or bases:

35 benzene-1,2,4,5-tetracarboxylic (pyromellitic)
benzene-1,2,3-tricarboxylic (hemimellitic)

	dimethylmalonic
	histidine
	hydroxylamine
5	carbonic ($H_2CO_3+CO_2$)
	malonic
	2-(<i>N</i> -morpholino)-ethane sulfonic acid "MES"
	glycerophosphoric
	propane-1,2,3-tricarboxylic (tricarballylic)
	benzenepentacarboxylic
10	maleic
	2,2-dimethylsuccinic
	ethylenediaminetetraacetic acid "EDTA"
	3,3-dimethylglutaric
	bis(2-hydroxyethyl)imino-tris(hydroxymethyl)methane "BIS-TRIS"
15	benzenehexacarboxylic (mellitic)
	<i>N</i> -(2-acetamido)imino-diacetic acid "ADA"
	butane-1,2,3,4-tetracarboxylic
	pyrophosphoric
	1,1-cyclopentanediacetic (3,3 tetramethylene-glutaric acid)
20	1,4-piperazinebis-(ethanesulfonic acid) "PIPES"
	<i>N</i> -(2-acetamido)-2-aminoethanesulfonic acid "ACES"
	1,1-cyclohexanediacetic
	3,6-endomethylene-1,2,3,6-tetrahydrophthalic acid "EMTA"
	("ENDCA")
25	imidazole
	2-(aminoethyl)trimethylammonium chloride "CHOLAMINE"
	<i>N,N</i> -bis(2-hydroxyethyl)-2-aminoethanesulfonic acid "BES"
	2-methylpropane-1,2,3-tricarboxylic (β -methyltricarballylic)
	2-(<i>N</i> -morpholino)propane-sulfonic acid "MOPS"
30	phosphoric
	<i>N</i> -tris(hydroxymethyl)methyl-2-aminoethane sulfonic acid "TES"
	<i>N</i> -2-hydroxyethylpiperazine- <i>N'</i> -2-ethanesulfonic acid "HEPES"

In the foregoing list, the name of the compound in parentheses is the common
35 name of the compound that precedes the name of the compound in
parentheses. The acronym set off by quotation marks is the name of the

compound commonly used when ordering the compound that precedes the acronym set off by quotation marks.

5 The buffer should be present in an amount sufficient to carry out its intended function, i. e., maintenance of the desired pH. Effective concentrations of the biological buffer can range from about 10 millimoles per liter to about 500 millimoles per liter (mM), more preferably from about 10 mM to about 100 mM. The preferred buffer is the buffer that goes by the acronym "MES".

10 The function of the dithiothreitol is to protect sulfhydryl groups in a protein. By protecting sulfhydryl groups in a protein, dithiothreitol allows the antigens, e.g., antigens of HCV, to retain their characteristic structure, thereby allowing recognition of antigens by their complementary antibodies. Dithiothreitol is described in detail in the brochure entitled "Cleland's Reagent", published by Calbiochem-Novabiochem Corporation, San Diego, California, incorporated herein by reference. As used herein, the term "dithiothreitol" 15 includes both dithiothreitol and its isomer dithioerythritol. The dithiothreitol should be present in an amount sufficient to carry out its intended function, i. e., to protect sulfhydryl groups in a protein. As used herein, "protect sulfhydryl groups" means to repress oxidation of sulfhydryl groups in a protein to disulfide groups while not affecting disulfide groups already present in the protein 20 groups. Effective concentrations of the dithiothreitol can range from about 2 millimoles per liter to about 10 millimoles per liter (mM), preferably from about 5 mM to about 10 mM, and more preferably about 10 mM.

25 The function of ethylene glycol is to prevent dithiothreitol from oxidation by oxidizing agents. For example, in the absence of ethylene glycol, dithiothreitol will be oxidized, thereby rendering dithiothreitol less effective for protecting sulfhydryl groups. Ethylene glycol is a 1,2-diol. Ethylene glycol was found to be superior to similar polyhydric alcohols or polymers, such as glycerol, polyethylene glycol, and polyvinyl acetate, with respect to the ability to preserve the binding capacity of antibodies, e.g., anti-HCV antibodies, to antigens. e.g., 30 HCV antigens. Ethylene glycol should be present in an amount sufficient to protect dithiothreitol from oxidation. Effective concentrations of the ethylene glycol can range from about 4% to about 8%, preferably from about 4% to about 5%, and more preferably about 4%, based on weight per unit volume (g/100 ml).

35 It is highly desirable to include at least one biological detergent, at least one source of positive and negative counterions, e.g., a salt, and at least one

viscosity modifier, e.g., a sugar in the composition of this invention in order to carry out effective immunoassays.

One function of the biological detergent (surfactant) is to reduce non-specific binding of antibodies other than the analyte antibodies, e.g., anti-HCV antibodies, to the microparticles. In other words, antibodies other than the analyte antibodies may adhere to the solid phase in the immunoassay for reasons other than the specific recognition of their complementary antigen. This non-specific binding is undesirable as it leads to false positive results. Biological detergents reduce the incidence of such binding caused by nonpolar or hydrophobic interactions.

Biological detergents (surfactants) that are useful in the composition include non-ionic surfactants, anionic surfactants, zwitterionic surfactants, and cationic surfactants. Non-ionic detergents include polyoxyethylene sorbitan monolaurate ("TWEEN® 20"), polyoxyethylene sorbitan monooleate ("TWEEN® 80"), polyoxyethylene ethers ("TRITON®", "BRIJ®"), and octylphenol-ethylene oxide ("NONIDET®"). Anionic surfactants include caprylic acid, cholic acid, deoxycholic acid, glycocholic acid and sodium dodecyl sulfate. Zwitterionic surfactants include "CHAPS®" (3-[3-Cholamidopropyl]-dimethylammonio]-1-propanesulfonate). Cationic detergents include cetylpyridinium chloride. It is preferred that non-ionic detergents be used for the reason that they are known to reduce non-specific binding while simultaneously not inhibiting specific binding. Effective concentrations of the biological detergent can vary from detergent to detergent, but can typically range from about 0.01% to about 1%, preferably about 0.01%, based on weight per unit volume (g/100 ml). The preferred detergent is Triton ® X-100.

The function of the source of positive and negative counterions (cations and anions) is to reduce non-specific binding of antibodies other than the analyte antibodies, e.g., anti-HCV antibodies, to the microparticles. In other words, antibodies other than the analyte antibodies may adhere to the solid phase in the immunoassay for reasons other than the specific recognition of their complementary antigen. This non-specific binding is undesirable as it leads to false positive results. Positive and negative counterions reduce the incidence of such binding caused by ionic interactions.

Suitable sources of positive and negative counterions include salts. Salts that are useful in the composition include such salts as NaCl and KCl. Effective concentrations of the salt can range from about 0.05 moles per liter to

about 0.5 moles per liter (M), preferably from about 0.1 M to about 0.3 M, and most preferably from about 0.15 M to about 0.25 M.

The function of the viscosity modifier is to increase the viscosity of a solution containing microparticles so that the microparticles more easily remain suspended in the solution and can be inhibited from settling. The use of a viscosity modifier in a diluent for microparticles has been found to achieve neutral density of the microparticles. Achievement of neutral density entails the determination of the optimum concentration of viscosity modifier that will eliminate settling of the microparticles. The concentration of viscosity modifier required to achieve neutral density is assay specific and microparticle lot specific. The principle involves dissolving viscosity modifier in solution to increase the density of the diluent. When the density of the diluent and microparticles are equivalent, the microparticles will be in a suspended state. Suitable viscosity modifiers include sugars, thickeners, and other agents, such as, for example, metrizamide and metrizoic acid. Sugars that are useful in the composition include such sugars as sucrose, glucose, and mannitol. Effective concentrations of the sugar can range from about 5% to about 25%, preferably from about 7% to about 20%, and most preferably from about 10% to about 15%, based on weight per unit volume (g/100 ml).

The function of the preservative is to reduce microbial growth in the composition. Preservatives that are useful in the composition include sodium azide. Effective concentrations of the preservative can range from about 0.1% to about 1%, preferably from about 0.1% to about 0.5%, and most preferably from about 0.1% to about 0.2%, based on weight per unit volume (g/100 ml).

It is preferred that the pH of the composition be below 7.2, more preferably below 7.0, and most preferably from about 6.5 to about 6.7. It is preferred that the pH of the composition be below 7.2 because experimental evidence shows that the ability to maintain disulfide bonds in their reduced state rapidly disappears as the pH increases above 7.2, as evidenced by reduction of antigen stability.

In a preferred embodiment, the buffer of the present invention contains the following ingredients in the amounts indicated, wherein mM, M and % are as previously defined:

Ingredient	Amount
Biological buffer	10 mM to 100 mM
Biological detergent	0.01% to 1%
Source of positive and negative counterions (salt)	0.1 M to 0.3 M
Viscosity modifier (sugar)	7 % to 20%
Preservative	0.1% to 0.5%
Dithiothreitol	5 mM to 10 mM
Ethylene glycol	4% to 5%

5 The composition of the invention can be prepared simply by mixing the foregoing components in water in any order and taking care to ensure that the pH of the composition is adjusted to the proper level. The order of addition of ingredients is not critical.

10 The composition of the invention is useful as a diluent of assay components. The term "assay components", as used herein, means the solid phase that contains antigen for antibody capture, e.g., microparticles coated with antigen. In addition, assay components include commercial assay reagents such as polyclonal and/or monoclonal antibodies, particularly of IgG or IgM class, and fragments thereof; antigens and fragments thereof; antigenic lysates, recombinant proteins, synthetic peptides, and the like. It also is contemplated that inert assay materials, such as latex particles, magnetic 15 beads, microparticles and the like, if provided in a suspension, may be suspended in the composition of the invention, or if dilution of these materials in a suspension is desired, the dilution may be performed with the composition of the invention.

20 The composition of the invention may be used to dilute assay components prior to performing the assay itself. The composition is especially useful for diluting antigens that are used in determining the presence or absence of specific antibodies to HCV. An example of such a method of dilution is described at col. 37, line 20 through col. 41, line 21 of U.S. Patent No. 5,358,691.

25 In another aspect of the invention, the composition can be provided as a component of a kit. As used herein, the term "kit" means a collection of reagents

and associated materials, e.g., diluents, buffers, required to perform an assay. In the apparatus described in U.S. Patent No. 5,358,691, a form of a kit is shown in FIGS. 4A and 4B. The kit is referred to as a reagent pack. The composition of this invention can be packaged in one of the receptacles of the reagent pack.

5 The following non-limiting examples will further illustrate the invention. In the examples, all concentrations are based on moles per liter (M), millimoles per liter (mM), or per cent (grams per 100 milliliters).

10

EXAMPLES

EXAMPLE 1 AND COMPARATIVE EXAMPLES A-D

15 This example illustrates the effect of a composition containing a biological buffer, dithiothreitol, and ethylene glycol on the stability of hepatitis C virus (HCV) antigen under heat stress conditions.

A stock composition containing biological buffer was prepared by combining the following ingredients to arrive at the indicated concentrations:

20

Ingredient

Concentration

25

Biological buffer ("MES")

10 mM

Biological detergent ("TRITON® X-100")

0.01%

Salt (NaCl)

0.2 M

Sugar (sucrose)

11.5%

30

Preservative (sodium azide)

0.1%

Dithiothreitol

10 mM

35 Each of the following additives was added to a separate portion of the stock composition to form four modified stock compositions. Each additive and the concentration thereof are set forth below:

<u>Example</u>	<u>Additive</u>	<u>Concentration</u>	
1	Ethylene glycol	5%	
5	Comp. A	Polyethylene glycol	1%
Comp. B	Polyvinyl alcohol	1%	
10	Comp. C	Glycerol	5%
Comp. D	None	0%	

15 Microparticles (polystyrene, 0.8 micrometer average diameter, commercially available from Seradyn) were coated with HCV antigens. The antigens were HC43/c100, c200, and NS5. The 33c antigen was present in both the HC34 antigen and the c200 antigen. One set of microparticles was coated with the HC43/c100 antigen. A second set of microparticles was coated with the c200 antigen. A third set of microparticles was coated with the NS5 antigen. Coating of the microparticles was carried out by passive adsorption. All three sets of the coated microparticles were blended together and a portion of the resulting blend was introduced into each of the four modified stock solutions (Example 1 and Comparative Examples A, B, and C) and into the unmodified stock solution, which acted as a control (Comparative Example D).

20 The microparticles were used to detect antibodies in single marker specimens used in assay development, specifically, panels containing anti-HCV antibodies to viral core, c100, or 33c antigens, as well as a negative control. The negative control contained no antibodies. All tests were run in triplicate and averaged.

25 Each solution containing the coated microparticles was incubated for a period of approximately 12 days at each of the following temperatures:

30 2-8 °C
31 °C
37 °C

5 The solution containing glycerol severely reduced signal generation in the assay. Accordingly, this solution was not evaluated beyond the fourth day. The solution containing polyvinyl acetate also reduced signal generation in the assay. Accordingly, this solution was not evaluated beyond the fourth day. The
10 solutions containing glycol and polyethylene glycol and the control were maintained at their respective temperatures and tested on the twelfth day.

10 The assay employed to test the effect of the additives was a microparticle capture enzyme immunoassay, was similar to that described in U.S. Patent No. 5,358,691, wherein the enzyme was alkaline phosphatase and the enzyme substrate was 4-methylumbelliferyl phosphate. However, in this assay, the antigens were coated onto microparticles, the analyte in the test sample was anti-HCV antibody, and the enzyme was attached to anti-human IgG antibody to form the conjugate. The assay format was a sandwich assay wherein the antigen would bind to the anti-HCV antibody, which, in turn, would bind to the conjugate.

15 FIG. 1 shows the results for the experiments carried out under the most extreme heat stress conditions (37 °C for 12 days). FIG. 1 shows results for antibodies to the c100 antigen, the 33c antigen, and the negative control.

20 The composition containing ethylene glycol showed superiority over the control and the composition containing polyethylene glycol with respect to maintaining detection of 33c activity following subjection to extreme heat stress conditions.

25 The antigens used in the assay are described below. Individual blood or plasma donors or patients (based on clinical evaluation) may be tested for antibodies to HCV. The presence of these antibodies indicates that the individual (donor or patient) has been infected with HCV, may harbor infectious HCV, and may be capable of transmitting non-A, non-B hepatitis (NANBH).

30

HC43

35 The recombinant HCV protein HC43, expressed in *E. coli*, contains sequences of putative HCV core structural protein and HCV nonstructural protein NS3. HC43 is a fusion protein consisting of amino acids 1 to 150 and 1192 to 1457 of the HCV polyprotein. The amino acids 1192 to 1457 of the HCV polyprotein constitute the 33c antigen.

c100-3

5 The recombinant HCV protein c100-3, expressed in *Saccharomyces cerevisiae* (yeast), contains sequences of the putative HCV nonstructural proteins NS3 and NS4. c100-3 is a chimeric fusion region of 154 amino acids of human superoxide dismutase (SOD), five linker amino acids, amino acids 1569 to 1931 of the HCV polyprotein and an additional five linker amino acids at the carboxyl 10 terminus.

c200

15 The recombinant HCV protein c200 expressed in yeast contains HCV amino acids 1192 to 1931, presumed to encode the NS3 and NS4 regions of the HCV genome. c200 is a chimeric fusion protein with 154 amino acids of superoxide dismutase (SOD).

20

NS5

25 The recombinant HCV protein NS5, expressed in yeast, contains sequences of the putative HCV nonstructural protein NS5. NS5 is a chimeric fusion region of 154 amino acids of SOD and amino acids 2054 to 2995 of the HCV polyprotein.

30 A more detailed discussion of the hepatitis C viral genome can be found in Selby et al., "Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome", *Journal of General Virology* (1993), 74, 1103-1113, incorporated herein by reference.

35 Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.

WHAT IS CLAIMED IS:

1. An aqueous composition comprising:
5 at least one biological buffer in a concentration sufficient to maintain the pH at a level below about 7.2;
dithiothreitol in a concentration sufficient to protect sulfhydryl groups; and
ethylene glycol in a concentration sufficient to prevent oxidation of
10 dithiothreitol,
wherein said composition has a pH of below about 7.2.
2. The composition of claim 1 wherein said at least one biological buffer is present in a concentration ranging from about 10 mM to about 500 mM.
15
3. The composition of claim 1 wherein said at least one biological buffer is present in a concentration ranging from about 10 mM to about 100 mM.
4. The composition of claim 1 wherein said at least one biological
20 buffer is an acid or base selected from the group consisting of:
benzene-1,2,4,5-tetracarboxylic (pyromellitic);
benzene-1,2,3-tricarboxylic (hemimellitic);
dimethylmalonic;
25 histidine;
hydroxylamine;
carbonic ($H_2CO_3+CO_2$);
malonic;
2-(*N*-morpholino)-ethane sulfonic acid "MES";
30 glycerophosphoric;
propane-1,2,3-tricarboxylic (tricarballylic);
benzenepentacarboxylic;
maleic;
2,2-dimethylsuccinic;
35 ethylenediaminetetraacetic acid "EDTA";
3,3-dimethylglutaric;

5 bis(2-hydroxyethyl)imino-tris(hydroxymethyl)methane "BIS-TRIS";
benzenehexacarboxylic (mellitic);
N -(2-acetamido)imino-diacetic acid "ADA";
butane-1,2,3,4-tetracarboxylic;
pyrophosphoric;
1,1-cyclopentanediacetic (3,3 tetramethylene-glutaric acid);
1,4-piperazinebis-(ethanesulfonic acid) "PIPES";
N -(2-acetamido)-2-aminoethanesulfonic acid "ACES";
1,1-cyclohexanediacetic;
3,6-endomethylene-1,2,3,6-tetrahydrophthalic acid "EMTA"
("ENDCA");
imidazole;
2-(aminoethyl)trimethylammonium chloride "CHOLAMINE";
N,N -bis(2-hydroxyethyl)-2-aminoethanesulfonic acid "BES";
2-methylpropane-1,2,3-triscarboxylic (β -methyltricarballylic);
2-(*N* -morpholino)propane-sulfonic acid "MOPS";
phosphoric;
N -tris(hydroxymethyl)methyl-2-aminoethane sulfonic acid "TES";
and
N -2-hydroxyethylpiperazine-*N* '-2-ethanesulfonic acid "HEPES".

5. The composition of claim 1 wherein said at least one biological buffer has a pKa ranging from about 5.6 to about 7.6.

25 6. The composition of claim 1 wherein dithiothreitol is present in a
concentration ranging from about 2 mM to about 10 mM.

7. The composition of claim 1 wherein dithiothreitol is present in a concentration ranging from about 5 mM to about 10 mM.

30 8. The composition of claim 1 wherein ethylene glycol is present in a concentration ranging from about 4% to about 8%, wherein % means g/100 ml.

10. The composition of claim 1 further including at least one biological detergent in a concentration sufficient to reduce non-specific binding of antibodies other than anti-HCV antibodies to HCV antigen caused by non-ionic interactions.

5

11. The composition of claim 10 wherein said at least one biological detergent is present in a concentration ranging from about 0.01% to about 1%, wherein % means g/100 ml.

10

12. The composition of claim 1 wherein said at least one biological detergent is selected from the group consisting of non-ionic surfactants, anionic surfactants, zwitterionic surfactants, and cationic surfactants.

15

13. The composition of claim 12 wherein said at least one biological detergent is a non-ionic surfactant.

14. The composition of claim 13 further comprising an anionic surfactant.

20

15. The composition of claim 1 further including at least one source of positive and negative counterions in a concentration sufficient to reduce non-specific binding of antibodies other than anti-HCV antibodies to HCV antigen caused by ionic interactions

25

16. The composition of claim 15 wherein said at least one source of positive and negative counterions is present in a concentration ranging from about 0.05 M to about 0.5 M.

30

17. The composition of claim 15 wherein said at least one source of positive and negative counterions is present in a concentration ranging from about 0.1 M to about 0.3 M.

18. The composition of claim 15 wherein said at least one source of positive and negative counterions is a salt.

35

19. The composition of claim 18 wherein said salt is selected from the group consisting of NaCl and KCl.

20. The composition of claim 1 further including at least one viscosity 5 modifier in a concentration sufficient to increase viscosity of a solution containing microparticles suspended therein so that settling of said microparticles suspended therein will be reduced.

21. The composition of claim 20 wherein said at least one viscosity 10 modifier is present in a concentration ranging from about 5% to about 25%, wherein % means g/100 ml.

22. The composition of claim 20 wherein said at least one viscosity 15 modifier is present in a concentration ranging from about 7% to about 20%, wherein % means g/100 ml.

23. The composition of claim 20 wherein said at least one viscosity modifier is a sugar.

20 24. The composition of claim 23 wherein said sugar is selected from the group consisting of sucrose, glucose, and mannitol.

25 25. The composition of claim 1 further including at least one preservative in a concentration sufficient to reduce microbial growth.

26. The composition of claim 25 wherein said at least one preservative is present in a concentration ranging from about 0.1% to about 1.0%, wherein % means g/100 ml.

30 27. The composition of claim 25 wherein said at least one preservative is present in a concentration ranging from about 0.1% to about 0.5%, wherein % means g/100 ml.

35 28. The composition of claim 1 wherein said at least one preservative is sodium azide.

29. The composition of claim 1 wherein said composition has a pH ranging from about 6.4 to about 6.8 .

5 30. The composition of claim 1 wherein said composition has a pH ranging from about 6.5 to about 6.7 .

10 31. An aqueous composition comprising:
at least one biological buffer;
dithiothreitol;
ethylene glycol;
at least one biological detergent;
at least one source of positive and negative counter ions ;
at least one viscosity modifier; and
at least one preservative;
15 wherein said composition has a pH ranging from about 6.4 to about 7.2 .

20 32. An aqueous composition comprising:
at least one biological buffer in a concentration in the range of from about 10 mM to about 500 mM;
dithiothreitol in a concentration in the range of from about 2 mM to about 10 mM;
ethylene glycol in a concentration in the range of from about 4% to about 8% ;
at least one biological detergent in a concentration in the range of from about 0.01% to about 1%;
at least one source of positive and negative counterions in a concentration in the range of from about 0.05 M to about 0.5 M;
at least one viscosity modifier in a concentration in the range of from about 5% to about 25%; and
30 at least one preservative in a concentration in the range of from about 0.1% to about 1%;
wherein said composition has a pH in the range of from about 6.4 to about 7.2, and wherein % means g/100 ml .

35 33. A kit for performing assays comprising the composition of claim 1.

34. A kit for performing assays comprising the composition of claim 10.
35. A kit for performing assays comprising the composition of claim 15.
- 5 36. A kit for performing assays comprising the composition of claim 18.
37. A kit for performing assays comprising the composition of claim 20.
- 10 38. A kit for performing assays comprising the composition of claim 23.
39. A kit for performing assays comprising the composition of claim 25.
40. A kit for performing assays comprising the composition of claim 31.
- 15 41. A kit for performing assays comprising the composition of claim 32.

1/1

Effect of Additives on HCV Antigen Stability




FIG. 1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/07745

A. CLASSIFICATION OF SUBJECT MATTER			
IPC 6	G01N33/50	G01N33/53	G01N33/543 //G01N33/576

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT
--

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB,A,2 193 500 (TAKARA SHUZO CO) 10 February 1988 see page 1, line 35 - line 41; examples 1-3 ---	1-41
X	EP,A,0 286 367 (MICROGENICS CORP) 12 October 1988 see page 4, line 12 - line 21 see page 5, line 32 - line 36 ---	1-41
X	PATENT ABSTRACTS OF JAPAN vol. 009, no. 066 (C-271), 26 March 1985 & JP,A,59 198999 (DENKA SEIKEN KK), 10 November 1984, see abstract ---	1-9,30

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.
--

<input checked="" type="checkbox"/> Patent family members are listed in annex.
--

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

*'&' document member of the same patent family

Date of the actual completion of the international search

2 October 1996

Date of mailing of the international search report
--

17.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Authorized officer

Cartagena y Abella, P

INTERNATIONAL SEARCH REPORT

International Application No	
PCT/US 96/07745	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI Section Ch, Week 9027 Derwent Publications Ltd., London, GB; Class A96, AN 90-209622 XP002014878 A,9 006 127 (OTSUKA PHARM KK) , 14 June 1990 see abstract & WO,A,90 06127 ---</p>	10-14, 20-24
A	<p>EP,A,0 363 105 (EASTMAN KODAK CO) 11 April 1990 see page 8, line 10 - line 55 see page 9, line 46 - page 10, line 1 ---</p>	1,4, 15-19, 25-29
A	<p>WO,A,93 06247 (ABBOTT LAB) 1 April 1993 see page 31, line 25-37 -----</p>	4,10-14, 25-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/07745

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB-A-2193500	10-02-88	JP-C-	1741492	15-03-93
		JP-B-	4030280	21-05-92
		JP-A-	63039582	20-02-88
		DE-A-	3725696	11-02-88
		US-A-	4868115	19-09-89
<hr/>				
EP-A-0286367	12-10-88	US-A-	4956274	11-09-90
		AU-B-	609112	26-04-91
		AU-A-	1417488	06-10-88
		CA-A-	1307220	08-09-92
		DE-A-	3872561	13-08-92
		ES-T-	2051838	01-07-94
		JP-A-	1085081	30-03-89
		JP-B-	6009510	09-02-94
<hr/>				
EP-A-0363105	11-04-90	US-A-	5075221	24-12-91
		DE-D-	68919982	26-01-95
		DE-T-	68919982	03-08-95
		JP-A-	2229861	12-09-90
		JP-B-	6070631	07-09-94
<hr/>				
WO-A-9306247	01-04-93	AU-A-	2679492	27-04-93
		EP-A-	0642666	15-03-95
		JP-T-	6510861	01-12-94